4basebio is a life sciences. Over the past three years, 4basebio has been involved in 1 licensing and acquisition transaction, with a primary focus on Gene Therapy (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Gene Therapy
Focus Area
Other
Licensing, acquisition, and partnership transactions involving 4basebio in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| hpDNA® | Genezen | Gene Therapy | Unknown | collaboration | Aug 26, 2026 |
Therapeutic areas and modalities where 4basebio is most active based on deal history and clinical trial data.
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
4basebio is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, 4basebio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for 4basebio include Other (2 deals and trials). In terms of modality, 4basebio has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for 4basebio and 700+ other biopharma companies. Use our Solidus to benchmark your asset against 4basebio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.